Constructive Bio

Constructive Bio provides a platform for genome and polymer synthesis, having pioneered methods for reprogramming the genetic code of living organisms to make them resistant to viruses and capable of producing synthetic polymers and performing entirely new functions. The technology has applications across novel therapeutics, antibiotics, enhanced agriculture, manufacturing, and materials. Founded in 2022 and headquartered in Saffron Walden, United Kingdom, Constructive Bio has raised $75M in Series A funding from investors including Ahren, Amadeus Capital, OMX Ventures, General Inception, Paladin Capital, Fine Structure Ventures, ND Capital, and LongeVC. The company's synthetic biology platform enables the creation of organisms with rewritten genetic codes that can incorporate non-standard amino acids into proteins, opening possibilities for producing novel biomaterials and therapeutics that cannot be made by natural biological systems.